Core Insights - Radiopharm Theranostics has increased its ownership stake in Radiopharm Ventures, LLC from 75% to 87.5% as the joint venture progresses in its cancer therapeutic pipeline [1][2] Group 1: Joint Venture and Ownership - The increase in ownership percentage reflects the promising progress of the joint venture, particularly with the B7H3 candidate and other preclinical assets [2] - Radiopharm Ventures, LLC was launched in September 2022 in collaboration with The University of Texas MD Anderson Cancer Center to develop novel radiopharmaceutical products for cancer treatment [5] Group 2: Product Development and Clinical Trials - The lead candidate, Betabart (RV01), is a monoclonal antibody targeting B7H3, which has received Investigational New Drug clearance from the U.S. FDA and is expected to begin dosing the first patient in Q1 2026 [3][7] - Two additional preclinical candidates have shown early positive results and are moving towards final candidate selection, with applications across multiple solid tumor types [4][7] Group 3: Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs, with a pipeline that includes one Phase 2 and four Phase 1 trials in various solid tumor cancers [6]